Microfluidic-based multi-organ platforms for drug discovery

Rezaei Kolahchi, A ; Sharif University of Technology

866 Viewed
  1. Type of Document: Article
  2. DOI: 10.3390/mi7090162
  3. Publisher: MDPI AG
  4. Abstract:
  5. Development of predictive multi-organ models before implementing costly clinical trials is central for screening the toxicity, efficacy, and side effects of new therapeutic agents. Despite significant efforts that have been recently made to develop biomimetic in vitro tissue models, the clinical application of such platforms is still far from reality. Recent advances in physiologically-based pharmacokinetic and pharmacodynamic (PBPK-PD) modeling, micro- and nanotechnology, and in silico modeling have enabled single- and multi-organ platforms for investigation of new chemical agents and tissue-tissue interactions. This review provides an overview of the principles of designing microfluidic-based organ-on-chip models for drug testing and highlights current state-of-the-art in developing predictive multi-organ models for studying the cross-talk of interconnected organs. We further discuss the challenges associated with establishing a predictive body-on-chip (BOC) model such as the scaling, cell types, the common medium, and principles of the study design for characterizing the interaction of drugs with multiple targets
  6. Keywords:
  7. Body-on-chip ; In silico modeling ; Organ-on-chip ; Biomimetics ; Crosstalk ; Drug interactions ; Drug products ; Medical applications ; Tissue ; Clinical application ; Drug discovery ; In-silico models ; Microfluidic-based ; New therapeutic agent ; On chips ; State of the art ; Tissue interactions ; Microfluidics
  8. Source: Micromachines ; Volume 7, Issue 9 , 2016 ; 2072666X (ISSN)
  9. URL: http://www.mdpi.com/2072-666X/7/9/162